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Abstract 
Recent studies have reported that cancer stem cells (CSCs) could be isolated from solid 
cancer cell lines, in which the purity of CSCs was higher than that from tumor tissues. Se-
paration of CSCs from leukemic cell lines was rarely reported. In this study, CD34
+CD38
- 
stem-like cell subsets in human KG-1a leukemic cell line were enriched by cytotoxic agent 
5-fluorouracil (5-FU). After 4 days incubation of KG-1a cell line with 5-FU (50 μg/ml), the 
CD34
+CD38
- subpopulation of cell lines was enriched more than 10 times. The enriched cells 
had proliferate potential in vitro, low level of RNA transcription and Hoechst 33342 dye efflux 
ability, accompanied by high expression of ATP-binding cassette transporter protein ABCG2. 
Our findings suggest that treatment with 5-FU offers an easy method to isolate leukemic 
stem-like subpopulation. It can facilitate studies of leukemic stem cell biology and the de-
velopment of new therapeutic strategies.  
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1. Introduction 
Increasing evidence suggests that a subpopula-
tion of cancer cells possesses extensive proliferative 
and self-renewal potential, and is responsible to tu-
mor growth. These cells were later named cancer stem 
cells (CSCs) [1]. The existence of CSCs was established 
in human acute myeloid leukemia (AML) [2]. As the 
firstly recognized CSCs, the biological characteristics 
of leukemic stem cells (LSCs) have been extensively 
studied. Compared to a majority of relatively mature 
leukemic cells in bone marrow, LSCs possess qualities 
reminiscent of normal hematopoietic stem cells 
(HSCs) including self-renewal, the capacity of mul-
ti-lineage differentiation and the potential to prolife-
rate extensively. Furthermore, LSCs are relatively 
quiescent and resistant to conventional chemothera-
py. LSCs are critical for the initiation and perpetua-
tion of leukemic disease, and their identification, 
characterization and isolation are essential to the de-
velopment of new therapeutic strategies [3]. Howev-
er, LSCs are only a small fraction of the total leukemic 
blasts, and they are difficult to identify and even more 
difficult to isolate. It is imperative to find a favorable 
method to isolate and purify LSCs, which may facili-
tate the understanding of biological characteristics of 
LSCs and provide basis for targeted therapy of leu-
kemia in clinical practice. 
Based on the biological similarities between 
LSCs and HSCs, the achievement in the exploration of 
surface markers of HSCs lays the foundation for the 




emergence of new techniques also facilitates the iden-
tification of LSCs. An in vivo study with non-obese 
diabetic-severe combined immunodeficient 
(NOD/SCID) mice indicated the ‘leukemia-initiating’ 
subpopulation expressing CD34 but not CD38. 
Therefore, LSCs can be isolated based on the 
CD34+CD38- phenotype using flow cytometry (FCM) 
[4]. However, there is a considerable overlap between 
normal CD34+CD38-  cells (HSCs) and malignant 
CD34+CD38- cells (LSCs). For the cells without specific 
phenotype, it is now possible to obtain CSC-like SP 
cells with FCM based on Hoechst 33342 efflux. Cells 
that exclude Hoechst 33342 have been termed “side 
population” (SP) cells [5]. SP cell analysis has been 
recently used to isolate CSCs from several types of 
cancers [6]. However, the level of SP cells in bone 
marrow of patients with leukemia is extremely low 
(median: 0.0016%), and the harvested cells frequently 
do not express CD34, which is an important marker of 
LSCs [7]. In addition, although absence of SP was 
observed in Abcg2-deficient mice, they were viable 
and demonstrated no defect in steady state hemato-
poiesis [8]. Therefore, the SP analysis was seldom 
used to enrich LSCs. Recently, Creighton et al found 
that the residual cancer cells after chemotherapy had 
tumor-initiating features [9]. Based on the facts that 
CSCs were in the quiescent state and resistant to 
chemotherapy, chemotherapeutic drugs, which act on 
cycling cell populations, are less effective on stem 
cells and may be applied in the isolation of CSCs. 
Therefore, cycle-specific chemotherapeutic agents 
have been a novel strategy for LSCs enrichment.  
No matter what kind of strategies used, ex-
tremely the low frequency of CSCs in any tumor tis-
sue and the difficulty in discriminating between 
normal tissue stem cells and CSCs has made their 
purification a highly challenging goal. Established 
cancer cell lines had acquired unlimited proliferation 
ability and may in fact retain stem cell patterns of 
behavior, which could be an attractive alternative 
source of cells for CSCs research. Nowadays, CSCs 
have been successfully separated from cell lines de-
rived from various solid cancers: including glioma 
[10], breast cancer [11], lung cancer [12], head and 
neck squamous carcinoma [13]. However, CSCs iso-
lated from hematological malignancies cell lines were 
rarely reported. Stem-like cells have been found in 
multiple myeloma (MM) cell lines [14], but have 
never been identified in leukemia cell lines. 
Cytotoxic agent 5-fluouracil (5-FU) had been 
applied to functional isolation and characterization of 
HSCs [15]. In the present study, we firstly enriched 
CD34+CD38- subpopulation from KG-1a cell lines by 
5-FU, and explored the stem-like biological features in 
vitro of the enriched cells.  
2. Materials and Methods 
2.1 Cell lines and culture conditions 
The human leukemic cell line KG1a was ob-
tained from the ATCC (Manassas, VA 20108, USA). 
Cells were cryopreserved and then rapidly thawed 
and suspended in RPMI 1640 (GIBCO-BRL, Grand 
Island, NY) containing 4 mmol/L L-glutamine, 1.5 
g/L sodium bicarbonate, and 20 % FBS (PAA, Aus-
tria). The line was maintained in an incubator at 37°C, 
95 % humidity, and 5 % CO2. Passage was performed 
every 3 to 4 days (as recommended by the ATCC). 
2.2 Incubation of KG-1a cells with 5-FU 
5-FU (Sigma, USA) was dissolved in PBS. The 
cells at the logarithmic growth phase were harvested 
and seeded at a density of 2×105  cells/ml in 5-ml 
flasks. 5-FU was added to the RPMI1640 supple-
mented 15% FBS at a final concentration of 0, 10, 20, 
30, 40, 50, 60 and 80 μg/ml, and cells were incubated 
at 37°C in a humidified air with 5 % CO2 for 24 h. Each 
experiment was performed in triplicate. Trypans blue 
staining was performed and viable cells were counted 
followed by averaging. The dose-response curve was 
drawn to determine the optimal concentration. With 
optimal concentration of 5-FU, the cells were main-
tained for consecutive 6 days for the determination of 
optimal duration. The optimal concentration and time 
were used in subsequent experiments for selecting 
LSC-like subpopulation.  
2.3 Flow cytometry assay  
Single cell suspension (106 cells/ml) was ob-
tained from KG-1a cells with or without 5-FU expo-
sure. The cells were incubated with mouse an-
ti-human CD45-PC5 antibody (Beckman Coulter, 
USA), CD34-PE antibody (Beckman Coulter, USA) 
and CD38-FITC antibody (Beckman Coulter, USA) at 
25°C in dark for 25 min. Subsequently, cells were 
rinsed with PBS twice and re-suspended in PBS con-
taining 1% paraformaldehyde for fixation. Mouse 
anti- human IgG1-PC5, mouse anti- human IgG1-PE 
and mouse anti- human IgG1-FITC were used for 
isotype control respectively, and negative control was 
established too. We located the cells through two pa-
rameter (CD45/SSC) scatter diagram.  
2.4 In vitro colony formation assay  
The KG-1a cells with or without 5-FU exposure 
were suspended in RPMI 1640 medium. Colony for-
mation assay was performed in semisolid culture 




USA) and 10 % FBS. The cell density was 
1×103/ml/plate and cells were incubated at 37°C for 
14 d. Routine colony counts were performed under an 
inverted microscope (XDS-1B, China). Aggregates of 
50 or more cells were scored as one colony and that of 
3~50 cells as one cluster. Colony-forming 
rate=number of colonies/1000×100%. Three inde-
pendent experiments were performed. 
2.5 Acridine orange staining 
The KG-1a cells were washed by the buffer de-
rived from the acridine orange kit (KeyGEN, Nan jing, 
China), and then prepared for single cell suspension 
(106 cells/ml). One volume of acridine orange was 
added to 19 volumes of cell suspension, and cells were 
incubated in the dark at room temperature for 15 min. 
Then, the cells were dropped onto slides and ob-
served under inverted fluorescence microscope 
(TE2000U, Nikon). Green fluorescence was observed 
when acridine orange combined to DNA, and orange 
fluorescence observed when acridine orange bound to 
RNA. A total of 5 randomly selected fields (×100) 
were used for counting. In each field, green and 
orange cells were counted, and the percentage of 
orange cells {orange cells / (green cells + orange cells) 
× 100%} was calculated. Three independent experi-
ments were performed. 
2.6 Hoechst 33342 staining 
The KG-1a cells with or without 5-FU exposure 
were centrifuged and re-suspended in 2 ml of RPMI 
1640 containing 2 % FBS. Then, the cells were incu-
bated with Hoechst 33342 (5 μg/ml; Sigma, USA) at 
37°C for 90 min and shaken well every 15 min. After 
washing with PBS twice, centrifugation was per-
formed followed by smearing. Cells were observed 
under inverted fluorescence microscope. Blue nucleus 
was observed when Hoechst33342 bound to DNA in 
the nucleus of viable cell. The cells with Hoechst 
33342 dye efflux ability showed negative/low stain-
ing. A total of 5 randomly selected fields (×100) were 
used for counting. In each field, the Hoechst 33342 
positive cells and total cells were counted, and the 
percentage of negative/low cells {(total cells-positive 
cells) / total cells × 100%} was calculated. Three in-
dependent experiments were performed. 
2.7 RT-PCR  
Total RNA of cells with or without 5-FU expo-
sure was extracted with RNArose. Then 2 mg of total 
RNA treated with DNA-free DNase was re-
verse-transcribed for cDNA synthesis and reverse 
transcription PCR (RT-PCR) was carried out.  The 
primers for ABCG2 were: 5’-GCTGGGTAATCCCC 
AGGCCTCT-3’, and 5’-AGAGATCGATGCCCTG 
CTTTACCA-3’; and those for β-actin were 
5’-AGCGAGCATCCCCCAAAGTT-3’ and 5’-GGGC 
ACGAAGGCTCATCATT-3’ (Invitrogen, Shanghai, 
China). The reaction was done in 50 μL volume con-
taining Expand High Fidelity buffer, 1.5 mM MgCl2, 
200 μM each dNTP, 0.2 μM each primer and 2.5 U Taq 
DNA polymerase. Cycling conditions were: 94°C for 5 
min, followed by 35 cycles at 94°C for 30 sec, 55°C for 
30 sec and 70°C for 50 sec, and a final extension step at 
72°C for 10 min. A total of 10 μl of PCR product was 
loaded onto agarose gel for electrophoresis. Optical 
density of ABCG2 and β-actin was analyzed with a 
gel imaging analysis system (BIO-RAD, USA) and 
relative expression of ABCG2 was calculated. 
2.8 Western blot  
Western blot assay was used for detection of 
ABCG2 protein expression. A total of 50 μg of pro-
teins was loaded into sodium dodecyl sulfate polya-
crylamide gel for electrophoresis and transferred onto 
PVDF member. The member was blocked with 5 % 
non-fat milk overnight at 4°C followed by incubation 
with primary antibody (mouse anti-human ABCG2 
monoclonal antibody; 1:100; R&D, USA) and second-
ary antibody (goat anti-mouse antibody; 2 h). Che-
miluminescence detection was performed after been 
washed. 
2.9 Statistical analysis 
All data were presented as mean ±SD and 
SPSS13.0 statistical software was used for Student’s 
paired t-test. A value of P<0.05 was considered statis-
tically significant.  
3. Results 
3.1 Selection of Stem-like cells by exposure to 
5-FU 
To determine a concentration of 5-FU selecting 
Stem-like cells, KG-1a cells were exposed at different 
concentrations ranging from 10 μg/ml to 50 μg/ml of 
5-FU for 24 h. We found that 5-FU could exert killing 
effect on cells in a dose-dependent manner, and 50 
μg/ml was the minimal concentration under which 
the survival rate of KG-1a was minimal. During the 
exposure of KG-1a with 50 μg/ml 5-FU for 6 d, results 
indicated the survival rate of KG-1a was in a 
time-dependent manner which reached the minimum 
on the day 4 (Figure 1). In subsequent experiments, 
KG-1a cells were incubated with 50 μg/mL 5-FU for 4 
d to select the stem-like cells. 
3.2 Enrichment of CD34
+CD38
- subpopulation  
After incubation with 5-FU, the KG-1a cells were 




accompanied by 23.0 % CD34-CD38- cells and 0.2 % 
CD34+CD38+ cells. Among the cells without 5-FU ex-
posure, the percentage of CD34+CD38- subset was 
only 7.02% and 85% KG-1a cells were CD34+CD38+ 
phenotype (Figure 2). These findings suggested after 
selecting by 5-FU, the proportion of CD34+CD38- 
subpopulation was elevated more than 10 times.
 
 
Figure 1. Dose-and time-dependent curves of 5-FU incubation with KG-1a cells. a, KG-1a cells were incubated with 
different concentrations of 5-FU for 24 h, and the killing effect of 5-FU was in a dose-dependent manner, with 50 μg / ml as 
the optimal concentration. b, KG-1a cells were incubated with 50 μg / ml 5-FU for different durations, and the killing effect 





Figure 2. Detection of CD34
+CD38
- subpopulation in KG-1a cells. It shows the flow cytometric analysis of CD34 and 
CD38 expression. FITC denotes fluorescein isothiocyanate, and PE phycoerythrin. a, KG-1a cells incubated at 50 μg/mL of 
5-FU for 4 d. The enriched cells had a high percentage of CD34
-CD38
- subpopulation. b, KG-1a cells.  
 





 3.3 In vitro clonogenic activity  
The results indicated that the colony-forming 
rate in the cells received 5-FU treatment was (11.5±8.7) 
%, and the number of colony-forming cells was 50~80. 
The colony-forming rate in the untreated cells was 
(5.4±2.1) %, majority of cells in this group formed 
clusters rather than colony in semisolid culture me-
dium. Results demonstrated that the colony-forming 
rate in cells received 5-FU treatment was markedly 





Figure 3. Colony formation assay in vitro semi-solid culture (Inverted microscope×400). a, (KG-1a +5-FU) group: KG-1a 
cells incubated at 50 μg/mL of 5-FU for 4 d. The enriched cells cultured in semisolid medium on 14 d formed clones and the 
number of colony forming cells was more than 50. b, KG-1a group: Majority of cells in this group only formed clusters. c, 
comparison on the colony-forming rate between two groups,*, p < 0.05. Error bars correspond to mean ± SD. 
 
3.4 Nucleic acid composition 
KG-1a cells were observed under inverted fluo-
rescence microscope after acridine orange staining. 
Green fluorescence was observed in the cells received 
5-FU treatment suggesting nucleic acid mainly con-
sisted of DNA accompanied by low level of RNA. 
Orange fluorescence was dominantly noted in the 
untreated cells implying nucleic acid mainly consisted 
of RNA (Figure 4). The percentage of the cells with 
orange fluorescence in the 5-FU treated group was 
(23.6±8.7) %, significantly lower than in 5-FU un-
treated group [(78.2±12.4) %, p<0.01]. These findings 
suggested the 5-FU resistant cells had low-level of 
RNA transcription.  






Figure 4. Acridine orange staining of nucleic acid in KG-1a cells (Fluorescence microscope ×200). a,  (KG-1a +5-FU) group: 
KG-1a cells incubated at 50 μg/mL of 5-FU for 4 d. The enriched cells had low level of RNA content; b, KG-1a group. c, 
comparison on the percentages of the cells with orange fluorescence between the two groups,*, p < 0.05. Error bars 
correspond to mean ± SD. The green fluorescence represents DNA content and the orange fluorescence represents RNA 
content. Three independent experiments were performed. A representative of the experimental results was shown.  
 
3.5 Hoechst 33342 efflux capacity  
After incubated with Hoechst 33342, the cells 
with Hoechst 33342 dye efflux ability showed neg-
ative/low staining. The negative/low cells rate was 
15.9% in (KG-1a +5-FU) group, significantly higher 
than in KG-1a group (6.6%, p<0.01). (Figure 5) 
 
Figure 5. The Hoechst 33342 negative/low staining cells 
rate in KG-1a cells. KG-1a cells were stained by Hoechst 
33342 and the cells were observed under inverted flu-
orescence microscope. Three independent experiments 
were performed. (KG-1a +5-FU) group: KG-1a cells 
incubated at 50 μg/mL of 5-FU for 4 d. The enriched cells 
had a high percentage of negative/low staining cells *, p < 




3.6 Expression of ABCG2 
PCR assay indicated the expression level of 
ABCG2 mRNA (701 bp) in cells received 5-FU treat-
ment was markedly higher than in the untreated cells. 
Western blot assay showed the expression of ABCG2 
protein (70 KDa) in cells received 5-FU treatment was 
dramatically higher than in untreated cells (Figure 6). 
 
 
Figure 6. Expression of ABCG2 mRNA and protein in KG-1a cells. The enriched cells had high expression of ABCG2 
mRNA and protein. a, analysis by RT-PCR of expression of ABCG2 mRNA. b, analysis by Western blotting of the ex-
pression of ABCG2 protein. +5-FU: KG-1a cells incubated with 50 μg/mL of 5-FU for 4 d; -5-FU: KG-1a cells without 5-FU. 
 
4. Discussions  
Evidence suggests that CSCs are integral to the 
development of several forms of human cancer. Effort 
now focused on identifying and isolating CSCs. 
Cell-sorting technologies based on the CSCs markers 
or Hoechst dye exclusion have proven to be successful 
in the isolation of CSCs. However, the amount of 
CSCs isolated from fresh cancer tissues is extremely 
low. Furthermore, experiments with primary cancer 
cells are costly and difficult to control because of small 
sample size and the heterogeneous nature of the cel-
lular among patient tissue samples. Recently, some 
studies indicated that solid cancer cell lines may pro-
vide us an alternative and convenient source of CSCs 
[16], but few studies reported the isolation of CSCs 
from hematological malignancies cell lines. 
L S C s  a r e  m a i n l y  i s o l a t e d  f r o m  b o n e  m a r r o w  
through puncture, however, these cells are frequently 
contaminated by HSCs and in vitro culture is difficult, 
which limit the application of this method. In this 
study, we enriched stem-like subpopulation from 
KG-1a cell lines by cytotoxic agent 5-FU. Numerous 
leukemic cell lines have been established and acute 
myeloid leukemia (AML) from subtype M0 to M7 has 
their own cell lines. KG-1a cells are derived from un-
differentiated cell line of AML subtype (AML-M0) 
and highly express stem cell-associated surface 
marker CD34 [17]. Therefore, KG-1a is an ideal cell 
model for enrichment of LSCs. It is well known that 
LSCs are in the quiescent state which makes them 
insensitive to chemotherapy. The cells in the prolife-
ration phase are killed by cell cycle-specific chemo-
therapeutic agents. 5-FU, a pyrimidine antagonist, can 
lead to interruption of DNA synthesis and arrest of 
cellular division and proliferation. In the present 
study, it was used to isolate LSCs-like cells and the 
optimal conditions (50 μg/ml 5-FU for 4 days) were 
established. The percentage of CD34+CD38- subpo-
pulation (76.8 %) in KG-1a cells incubated with 5-FU 
was nearly increased by 10 folds. Although not all 
LSCs can be defined as CD34+CD38- [18], LSCs are 
detected only within the CD34+CD38- fraction of most 
AML samples [2, 19], so the CD34+CD38- subpopula-
tion was often used to represent LSCs in AML [20]. 
Colony-forming assay is an effective tool to test pro-
liferating ability of single cell. The colony-forming 
rate of the cells received 5-FU treatment was elevated, 
indicating its proliferative potential in vitro. Mean-
while, it is also possible that cells under the stress 
condition (i.e., 5-FU exposure) simultaneously enter 
cell cycle after release from the stress (removal of 
5-FU) and start proliferation. In the present study, the 
5-FU resistant cells showed orange fluorescence in 
acridine orange staining test, which indicated the 
low-level of RNA transcription and quiescent consis-
tent with stem cell biology. In addition, after 5-FU 
exposure, the percentage of Hoechst 33342 negatively 
stained cells increased. The cells that exclude fluores-
cent dyes Hoechst 33342 are defined side population 
(SP) cells and these cells share characteristics of CSCs, 
so further studies are required to detect the propor-
tion of SP cells by FCM. Recent evidence suggests that 
the Hoechst 33342 dye efflux ability is probably me-
diated by an ABCG2-related mechanism and the ex-
pression of ABCG2 in LSCs was higher than in pro-
genitors [21]. In this study, the cells received 5-FU 
treatment had high expression of ABCG2, which 
might originated from LSCs compartment and 
drug-resistant leukemic cells. In fact, some studies 
indicated that there were some overlap between 
drug-resistant cells and cancer stem cells. One study 




tions surviving after conventional treatment may be 
enriched for subpopulations of cells with tu-
mor-initiating [9].  
In vitro incubations with 5-FU have been used 
for enrichment of normal primitive hematopoietic 
stem cells [15], It has also been found 5-FU was ap-
plied to enrich LSCs from primary AML cells [22] and 
primary chronic myeloid leukemia (CML) cells [23], 
even though 5-FU seldom used for an antileukemic 
drugs in clinical practice. There are increasing evi-
dence suggested that chemotherapeutic drugs could 
be applied to separate CSC subpopulations, for ex-
ample, 1, 3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) 
used for enrichment of CSCs subset in human brain 
glioma [24], epirubicin used in breast cancer [25], and 
5-FU used in colorectal cancer [26]. Studies showed 
that LSCs in acute myeloid leukemia had the intrinsic 
drug efflux capacity [27], therefore, in the future 
study, more clinic relevant chemotherapy drugs (such 
as daunorubicin and mitoxantrone) should be tested 
in order to better simulate the clinic situation.  
In conclusion, our experiment was a preliminary 
study on enrichment of stem-like cells subset with 
cytotoxic agent from leukemic cell lines. Furthermore, 
this assay would be verified in primary leukemic cells 
and other antileukemic drugs. In addition, the leu-
kemia-initiating ability of the enriched cells com-
partment will need proof in animal models.  
Acknowledgements 
This project was supported by a grant from Na-
tional Science Foundation of China (No. 30872418) 
and Science and Technology Research Foundation of 
Chongqing Municipal Education Commission (No. 
KJ050309). We would like to appreciate Mr. Qianglin 
Duan for critical reading of the manuscript.  
Conflict of Interests 
The authors have declared that no conflict of in-
terest exists. 
References 
1.  Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and 
cancer stem cells. Nature. 2001; 414: 105–11. 
2.  Bonnet D, Dick JE. Human acute myeloid leukemia is organized 
as a hierarchy that originates from a primitive hematopoietic 
cell. Nat Med.1997; 3: 730-7. 
3.  Chan WI, Huntly BJ. Leukemia stem cells in acute myeloid 
leukemia. Semin Oncol. 2008; 35: 326-35. 
4.  Bhatia M, Wang JC, Kapp U, et al. Purification of primitive 
human hematopoietic cells capable of repopulating im-
mune-deficient mice. Proc Natl Acad Sci U S A. 1997; 94: 5320-5. 
5.  Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct "side 
population" of cells with high drug efflux capacity in human 
tumor cells. Proc Natl Acad Sci U S A. 2004; 101: 14228-33. 
6.  Wu C, Alman BA. Side population cells in human cancers. 
Cancer Lett. 2008; 268: 1-9.  
7.  Moshaver B, van Rhenen A, Kelder A, et al. Identification of a 
small subpopulation of candidate leukemia-initiating cells in 
the side population of patients with acute myeloid leukemia. 
Stem Cells.2008; 26: 3059-67. 
8.  Zhou S, Morris JJ, Barnes Y, et al. Bcrp1 gene expression is 
required for normal numbers of side population stem cells in 
mice, and confers relative protection to mitoxantrone in hema-
topoietic cells in vivo. Proc Natl Acad Sci U S A.2002; 99: 
12339-44. 
9.  Creighton CJ, Li X, Landis M, et al. Residual breast cancers after 
conventional therapy display mesenchymal as well as tu-
mor-initiating features. Proc Natl Acad Sci U S A. 2009; 106: 
13820-5. 
10.  Qiang L, Yang Y, Ma YJ, et al. Isolation and characterization of 
cancer stem like cells in human glioblastoma cell lines. Cancer 
Lett. 2009; 279: 13-21.  
11.  Fillmore CM, Kuperwasser C. Human breast cancer cell lines 
contain stem-like cells that self-renew, give rise to phenotypi-
cally diverse progeny and survive chemotherapy. Breast Cancer 
Res. 2008; 10: R25. 
12.  Ho MM, Ng AV, Lam S, et al. Side population in human lung 
cancer cell lines and tumors is enriched with.stem-like cancer 
cells. Cancer Res. 2007; 67: 4827-33. 
13.  Huang D, Gao Q, Guo L, et al. Isolation and identification of 
cancer stem-like cells in esophageal carcinoma cell lines. Stem 
Cells Dev. 2009; 18: 465-73.  
14.  Matsui W, Huff CA, Wang Q, et al. Characterization of clono-
genic multiple myeloma cells. Blood. 2004; 103: 2332-6.  
15.  Berardi AC, Wang A, Levine JD, et al. Functional isolation and 
characterization of human hematopoietic stem cells. Science. 
1995; 267: 104-8. 
16.  Kondo T. Stem cell-like cancer cells in cancer cell lines. Cancer 
Biomark. 2007; 3: 245-50. 
17.  Koeffler HP, Billing R, Lusis AJ, et al. An undifferentiated va-
riant derived from the human acute myelogenous leukemia cell 
line (KG-1). Blood.1980; 56: 265-73.  
18.  Taussig DC, Miraki-Moud F, Anjos-Afonso F, et al. Anti-CD38 
antibody–mediated clearance of human repopulating cells 
masks the heterogeneity of leukemia-initiating cells. Blood, 
2008; 112: 568-75. 
19.  Blair A, Hogge DE, Ailles LE, et al. Lack of expression of Thy-1 
(CD90) on acute myeloid leukemia cells with long-term proli-
ferative ability in vitro and in vivo. Blood. 1997; 89: 3104-12. 
20.  Florian S, Sonneck K, Hauswirth AW, et al. Detection of mole-
cular targets on the surface of CD34+/CD38-- stem cells in 
various myeloid malignancies. Leuk Lymphoma. 2006; 47: 
207-22. 
21.  de Figueiredo-Pontes LL, Pintão MC, Oliveira LC, et al. Deter-
mination of P-glycoprotein, MDR-related protein 1, breast 
cancer resistance protein, and lung-resistance protein expres-
sion in leukemic stem cells of acute myeloid leukemia. Cyto-
metry B Clin Cytom. 2008; 74: 163-8. 
22.  Terpstra W, Ploemacher RE, Prins A, et al. Fluorouracil selec-
tively spares acute myeloid leukemia cells with long- term 
growth abilities in immunodeficient mice and in culture. Blood. 
1996; 88: 1944-50. 
23.  Holyoake T, Jiang X, Eaves C, et al. Isolation of a highly quies-
cent subpopulation of primitive leukemic cells in chronic mye-
loid leukemia. Blood. 1999; 94: 2056-64. 
24.  Kang MK, Kang SK. Tumorigenesis of chemotherapeutic 
drug-resistant cancer stem-like cells in brain glioma. Stem Cells 
Dev. 2007; 16: 837-47. 
25.  Yu F, Yao H, Zhu P, et al. let-7 regulates self renewal and tu-




26.  Pang R, Law WL, Chu AC, et al. A Subpopulation of CD26+ 
Cancer Stem Cells with Metastatic Capacity in Human Colo-
rectal Cancer. Cell Stem Cell. 2010; 6: 603-15. 
27.  Gerald G. Wulf, Rui-Yu Wang, Ingrid Kuehnle, et al. A leu-
kemic stem cell with intrinsic drug efflux capacity in acute 
myeloid leukemia. Blood. 2001; 98: 1166-73. 